Leuprorelin acetate blood levels and dialysance after the administration of sustained-release leuprorelin acetate in a dialysis case complicated by prostate cancer

BACKGROUND The objective of this study is to determine whether in a dialysis patient with prostate cancer leuprorelin acetate blood levels were abnormally high or low due to kidney failure or because of dialysis. METHODS Sustained‐release leuprorelin acetate 3.75 mg was given every 4 weeks for prost...

Full description

Saved in:
Bibliographic Details
Published in:The Prostate 1998-02, Vol.34 (3), p.191-194
Main Authors: Saruki, Kazuhisa, Sekihara, Tetsuo, Mashimo, Masamichi, Matsuo, Hidenori, Sekiguchi, Hiroyuki
Format: Article
Language:English
Subjects:
Aged
Antineoplastic agents
Antineoplastic Agents, Hormonal - administration & dosage
Antineoplastic Agents, Hormonal - blood
Biological and medical sciences
Chemotherapy
dialysis
Humans
Leuprolide - administration & dosage
Leuprolide - blood
leuprorelin
Male
Medical sciences
neoplasms
Pharmacology. Drug treatments
prostate
Prostatic Neoplasms - blood
Prostatic Neoplasms - complications
Prostatic Neoplasms - drug therapy
Renal Dialysis
Renal Insufficiency - blood
Renal Insufficiency - complications
Renal Insufficiency - therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND The objective of this study is to determine whether in a dialysis patient with prostate cancer leuprorelin acetate blood levels were abnormally high or low due to kidney failure or because of dialysis. METHODS Sustained‐release leuprorelin acetate 3.75 mg was given every 4 weeks for prostate cancer in a 79‐year‐old dialysis patient. Changes in serum level of leuprorelin acetate in this patient were measured before and after dialysis. RESULTS Leuprorelin acetate appeared to have a dialysance close to that of vitamin B12, which has a similar molecular weight. The amount dialyzed did not exceed 8.3% of the amount released per day. Mean blood levels of leuprorelin acetate, as measured in this patient, were higher (0.64 to 1.31 ng/ml) than those in prostate cancer patients with normal kidney function (mean ± SD, 0.24 ± 0.12 to 0.50 ± 0.32 ng/ml). CONCLUSIONS Sustained‐release leuprorelin acetate can be used safely in dialysis patients with prostate cancer. Prostate 34:191–194, 1998. © 1998 Wiley‐Liss, Inc.
ISSN:0270-4137
1097-0045
DOI:10.1002/(SICI)1097-0045(19980215)34:3<191::AID-PROS6>3.0.CO;2-L